FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pediatric nephrology, and can be used for assessing the clinical effectiveness of children with nephrotic syndrome in remission. That is ensured by administering an immunosuppressive agent with an angiotensin-converting enzyme inhibitor 2.5 mg a day in the morning once; before the beginning of treatment, 6 and 12 months later, the patient is exposed to ultrasonic Doppler sonography of the renal vessels with evaluation of blood flow parameters, determined glomerular filtration rate by Schwartz formula; if in 6 months normalization of blood flow parameters is observed, absence of glomerular filtration decrease in comparison with data obtained before the treatment, then the treatment regimen is left unchanged for another 6 months, wherein in normalizing blood flow parameters 12 months after the beginning of treatment, the immunosuppressive preparation is canceled; if no blood flow parameters normalization is observed in 6 months, reducing the glomerular filtration rate as compared to the pre-treatment data, the therapy regimen is supplemented with the angiotensin II receptor blocker application in the nephroprotective dose, and the angiotensin-converting enzyme inhibitor dose is increased to 5 mg, and further evaluating clinical effectiveness 6 and 12 months after the treatment regimen is changed; in the absence of recurrences and positive dynamics of the results of test methods 12 months after the beginning of therapy, its effectiveness is considered to be high and the therapeutic regimen excludes the immunosuppressive preparation and the angiotensin receptor blocker if previously prescribed; with recurrence of the disease, no positive dynamics of the results of examination methods 12 months after the beginning of the therapy, the therapy regimen is preserved in full.
EFFECT: method enables optimizing treatment of children by increasing renal survival.
1 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING RISK OF PROGRESSION OF CHRONIC RENAL DISEASE IN CHILDREN | 2015 |
|
RU2605575C1 |
METHOD OF PREDICTING PROGRESSING COURSE OF STEROID-RESISTANT NEPHROTIC SYNDROME IN CASE OF GLOMERULONEPHRITIS IN CHILDREN | 2009 |
|
RU2414852C1 |
METHOD FOR TREATING GLOMERULONEPHRITES WITH NEPHROTIC SYNDROME WITH A RELAPSING COURSE | 2020 |
|
RU2764216C1 |
METHOD FOR PREDICTING TUBULO-INTERSTITIAL KIDNEY DISEASE IN CHILDREN ASSOCIATED WITH HEMOLYTIC-UREMIC SYNDROME | 2021 |
|
RU2782125C1 |
DIAGNOSTIC TECHNIQUE FOR NEPHROTIC SYNDROME WITH MINIMAL CHANGES IN CHILDREN | 2013 |
|
RU2522238C1 |
METHOD FOR PREDICTION OF PESPONSE RATE TO IMMUNOSUPPRESSIVE THERAPY OF CHRONIC GLOMERULONEPHRITIS WITH NEPHROTIC SYNDROME | 2011 |
|
RU2453852C1 |
METHOD FOR DIAGNOSING EARLY CHRONIC RENAL DISEASE IN CHILDREN | 2020 |
|
RU2753581C1 |
METHOD FOR PREDICTION OF THE DYNAMICS OF INTRARENAL VASCULAR RESISTANCE AND GLYCATED HEMOGLOBIN IN THE PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS 30 WEEKS AFTER THE BEGINNING OF THE ANTIHYPERTENSIVE THERAPY | 2018 |
|
RU2694505C1 |
METHOD OF ASSESSING EFFECTIVENESS OF NEPHROPROTECTIVE THERAPY IN HYPERTENSIVE PATIENTS WITH STAGE C2 CHRONIC KIDNEY DISEASE | 2023 |
|
RU2810453C1 |
METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
Authors
Dates
2020-09-29—Published
2020-03-27—Filed